| The national lung screening trial: overview and study design National Lung Screening Trial Research Team Radiology 258 (1), 243-253, 2011 | 1312 | 2011 |
| Probability of cancer in pulmonary nodules detected on first screening CT A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ... New England journal of medicine 369 (10), 910-919, 2013 | 1302 | 2013 |
| Selection criteria for lung-cancer screening MC Tammemägi, HA Katki, WG Hocking, TR Church, N Caporaso, ... New England Journal of Medicine 368 (8), 728-736, 2013 | 910 | 2013 |
| Overdiagnosis in low-dose computed tomography screening for lung cancer EF Patz, P Pinsky, C Gatsonis, JRD Sicks, BS Kramer, MC Tammemägi, ... JAMA internal medicine 174 (2), 269-274, 2014 | 834 | 2014 |
| Targeting of low-dose CT screening according to the risk of lung-cancer death SA Kovalchik, M Tammemagi, CD Berg, NE Caporaso, TL Riley, M Korch, ... New England Journal of Medicine 369 (3), 245-254, 2013 | 589 | 2013 |
| Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force HJ De Koning, R Meza, SK Plevritis, K Ten Haaf, VN Munshi, J Jeon, ... Annals of internal medicine 160 (5), 311-320, 2014 | 518 | 2014 |
| Comorbidity and survival disparities among black and white patients with breast cancer CM Tammemagi, D Nerenz, C Neslund-Dudas, C Feldkamp, ... Jama 294 (14), 1765-1772, 2005 | 468 | 2005 |
| Smoking and lung cancer survival: the role of comorbidity and treatment CM Tammemagi, C Neslund-Dudas, M Simoff, P Kvale Chest 125 (1), 27-37, 2004 | 342 | 2004 |
| Impact of comorbidity on lung cancer survival CM Tammemagi, C Neslund‐Dudas, M Simoff, P Kvale International journal of cancer 103 (6), 792-802, 2003 | 337 | 2003 |
| Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts MC Tammemaegi, TR Church, WG Hocking, GA Silvestri, PA Kvale, ... PLoS medicine 11 (12), e1001764, 2014 | 336 | 2014 |
| Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation CM Tammemagi, PF Pinsky, NE Caporaso, PA Kvale, WG Hocking, ... Journal of the national cancer institute 103 (13), 1058-1068, 2011 | 324 | 2011 |
| Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate GY Jin, D Lynch, A Chawla, K Garg, MC Tammemagi, H Sahin, S Misumi, ... Radiology 268 (2), 563-571, 2013 | 281 | 2013 |
| Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study K Ten Haaf, J Jeon, MC Tammemägi, SS Han, CY Kong, SK Plevritis, ... PLoS medicine 14 (4), e1002277, 2017 | 273 | 2017 |
| Impact of lung cancer screening results on smoking cessation MC Tammemägi, CD Berg, TL Riley, CR Cunningham, KL Taylor Journal of the National Cancer Institute 106 (6), dju084, 2014 | 223 | 2014 |
| Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study MC Tammemagi, H Schmidt, S Martel, A McWilliams, JR Goffin, ... The lancet oncology 18 (11), 1523-1531, 2017 | 205 | 2017 |
| Long-term prognostic role of functional limitations among women with breast cancer D Braithwaite, WA Satariano, B Sternfeld, RA Hiatt, PA Ganz, ... Journal of the National Cancer Institute 102 (19), 1468-1477, 2010 | 165 | 2010 |
| Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada K Ten Haaf, MC Tammemägi, SJ Bondy, CM van der Aalst, S Gu, ... PLoS medicine 14 (2), e1002225, 2017 | 144 | 2017 |
| Hypertension is an independent predictor of survival disparity between African‐American and white breast cancer patients D Braithwaite, CM Tammemagi, DH Moore, EM Ozanne, RA Hiatt, ... International Journal of Cancer 124 (5), 1213-1219, 2009 | 144 | 2009 |
| In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival CM Tammemagi, C Neslund-Dudas, M Simoff, P Kvale Journal of clinical epidemiology 57 (6), 597-609, 2004 | 143 | 2004 |
| The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency S Cressman, SJ Peacock, MC Tammemägi, WK Evans, NB Leighl, ... Journal of Thoracic Oncology 12 (8), 1210-1222, 2017 | 139 | 2017 |
